BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

569 related articles for article (PubMed ID: 25833098)

  • 1. The Essential Role of Soluble Aβ Oligomers in Alzheimer's Disease.
    Wang ZX; Tan L; Liu J; Yu JT
    Mol Neurobiol; 2016 Apr; 53(3):1905-1924. PubMed ID: 25833098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The pathophysiology of Alzheimer's disease with special reference to "amyloid cascade hypothesis"].
    Tamaoka A
    Rinsho Byori; 2013 Nov; 61(11):1060-9. PubMed ID: 24450113
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physicochemical characteristics of soluble oligomeric Abeta and their pathologic role in Alzheimer's disease.
    Watson D; Castaño E; Kokjohn TA; Kuo YM; Lyubchenko Y; Pinsky D; Connolly ES; Esh C; Luehrs DC; Stine WB; Rowse LM; Emmerling MR; Roher AE
    Neurol Res; 2005 Dec; 27(8):869-81. PubMed ID: 16354549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Brain amyloid-β oligomers in ageing and Alzheimer's disease.
    Lesné SE; Sherman MA; Grant M; Kuskowski M; Schneider JA; Bennett DA; Ashe KH
    Brain; 2013 May; 136(Pt 5):1383-98. PubMed ID: 23576130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The case for soluble Aβ oligomers as a drug target in Alzheimer's disease.
    Hefti F; Goure WF; Jerecic J; Iverson KS; Walicke PA; Krafft GA
    Trends Pharmacol Sci; 2013 May; 34(5):261-6. PubMed ID: 23582316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.
    Zhang W; Hao J; Liu R; Zhang Z; Lei G; Su C; Miao J; Li Z
    Behav Brain Res; 2011 Sep; 222(2):342-50. PubMed ID: 21513747
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Large Soluble Oligomers of Amyloid β-Protein from Alzheimer Brain Are Far Less Neuroactive Than the Smaller Oligomers to Which They Dissociate.
    Yang T; Li S; Xu H; Walsh DM; Selkoe DJ
    J Neurosci; 2017 Jan; 37(1):152-163. PubMed ID: 28053038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrillar seeds alleviate amyloid-β cytotoxicity by omitting formation of higher-molecular-weight oligomers.
    Wu WH; Liu Q; Sun X; Yu JS; Zhao DS; Yu YP; Luo JJ; Hu J; Yu ZW; Zhao YF; Li YM
    Biochem Biophys Res Commun; 2013 Sep; 439(3):321-6. PubMed ID: 24012671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Involvement of beta-amyloid in the etiology of Alzheimer's disease].
    Tomiyama T
    Brain Nerve; 2010 Jul; 62(7):691-9. PubMed ID: 20675873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disruption of amyloid plaques integrity affects the soluble oligomers content from Alzheimer disease brains.
    Jimenez S; Navarro V; Moyano J; Sanchez-Mico M; Torres M; Davila JC; Vizuete M; Gutierrez A; Vitorica J
    PLoS One; 2014; 9(12):e114041. PubMed ID: 25485545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protofibrils of Amyloid-β are Important Targets of a Disease-Modifying Approach for Alzheimer's Disease.
    Ono K; Tsuji M
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32023927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease.
    De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
    Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinctive temporal profiles of detergent-soluble and -insoluble tau and Aβ species in human Alzheimer's disease.
    Koss DJ; Dubini M; Buchanan H; Hull C; Platt B
    Brain Res; 2018 Nov; 1699():121-134. PubMed ID: 30102892
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The coexistence of an equal amount of Alzheimer's amyloid-β 40 and 42 forms structurally stable and toxic oligomers through a distinct pathway.
    Chang YJ; Chen YR
    FEBS J; 2014 Jun; 281(11):2674-87. PubMed ID: 24720730
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the neurotoxic species in Alzheimer's disease: inhibitors of Abeta oligomerization.
    De Felice FG; Vieira MN; Saraiva LM; Figueroa-Villar JD; Garcia-Abreu J; Liu R; Chang L; Klein WL; Ferreira ST
    FASEB J; 2004 Sep; 18(12):1366-72. PubMed ID: 15333579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptides as Potential Therapeutics for Alzheimer's Disease.
    Ribarič S
    Molecules; 2018 Jan; 23(2):. PubMed ID: 29385735
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Study of Aβ Oligomers in the Temporal Cortex and Cerebellum of Patients with Neuropathologically Confirmed Alzheimer's Disease Compared to Aged Controls.
    Savioz A; Giannakopoulos P; Herrmann FR; Klein WL; Kövari E; Bouras C; Giacobini E
    Neurodegener Dis; 2016; 16(5-6):398-406. PubMed ID: 27400224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortical pyroglutamate amyloid-β levels and cognitive decline in Alzheimer's disease.
    Pivtoraiko VN; Abrahamson EE; Leurgans SE; DeKosky ST; Mufson EJ; Ikonomovic MD
    Neurobiol Aging; 2015 Jan; 36(1):12-9. PubMed ID: 25048160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloid-β: the seeds of darkness.
    Fodero-Tavoletti MT; Villemagne VL; Rowe CC; Masters CL; Barnham KJ; Cappai R
    Int J Biochem Cell Biol; 2011 Sep; 43(9):1247-51. PubMed ID: 21601003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid-β and tau: the trigger and bullet in Alzheimer disease pathogenesis.
    Bloom GS
    JAMA Neurol; 2014 Apr; 71(4):505-8. PubMed ID: 24493463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.